Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to determine the efficacy, based on PFS, of mFOLFOX6/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab
Shravan Kumar Narmala, MD
National Cancer Institute (NCI)
Type of Trial